Application of a new ultrasound criterion for the diagnosis of polycystic ovary syndrome
Metadata
Show full item recordEditorial
Frontiers
Materia
Pcos Ultrasound follicular count Hyperandrogenism Insulin resistance Infertility
Date
2022-09-02Referencia bibliográfica
Giménez-Peralta I... [et al.] (2022) Application of a new ultrasound criterion for the diagnosis of polycystic ovary syndrome. Front. Endocrinol. 13:915245. doi: [10.3389/fendo.2022.915245]
Abstract
Objective: To define which ultrasound criteria could replace the classic
Rotterdam criteria as the best indicator of the risk of developing endocrine–
metabolic changes in women with polycystic ovary syndrome (PCOS).
Materials and methods: This multicenter cross-sectional study included 200
women with PCOS and one control group of 111 women without PCOS. The
primary outcomes to be considered were follicular count, hirsutism, total
testosterone levels, free androgen index (FAI), and insulin sensitivity (HOMAIR),
and the secondary outcome was the anti-Müllerian hormone (AMH) level.
Results: The main finding in this study points toward a different ultrasound
criterion—23 or more follicles of any size in at least one ovary, which is
postulated as an alternative to the classic criterion described in the
Rotterdam consensus. This criterion correlates better with the other two
PCOS criteria and also identifies women at increased risk of hirsutism
(Ferriman–Gallwey score: 6.08 ± 3.54 vs. 4.44 ± 3.75, p < 0.0001), total
testosterone levels (2.24 ± 0.298 vs. 1.42 ± 1.530, p = 0.0001), FAI
(4.85 ± 0.83 vs. 2.12 ± 1.93, p < 0.001), and insulin resistance (HOMA-IR:
1.74 ± 0.182 vs. 1.504 ± 0.230, p = 0.001) more accurately. Regarding AMH,
large differences in their mean values were observed between the groups (7.07
vs. 4.846 ng/ml, p = 0.000). However, these differences depended on age.
Conclusion: The ovarian ultrasound examination with 23 or more follicles of
any size in any of the ovaries constitutes a powerful tool to accurately diagnose
PCOS and to associate it with metabolic–endocrine processes such as
hyperandrogenism and insulin resistance.